News

Alterity Therapeutics reports new data from ATH434 Phase 2 trial at AAN meeting
Alterity Therapeutics (ATHE) announced that new presentations related to its Multiple System Atrophy program were delivered at the American ...
Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...
Morningstar18d
Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy
MELBOURNE, Australia and SAN FRANCISCO, March 27, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a ...
Investing7d
Alterity Therapeutics completes placement
Alterity Therapeutics Limited (NASDAQ:ATHE), a pharmaceutical company specializing in the development of therapeutic drugs with a current market capitalization of $28 million, announced today the ...
ADVFN24d
Alterity Therapeutics Raises A$40.0 million in Placement
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or the “Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases ...
Investing7d
Alterity Therapeutics announces regulatory notice
Alterity Therapeutics Limited (market capitalization: $28 million), a pharmaceutical company in the development stage, has issued a regulatory notice under Section 708A, as disclosed in a Form 6-K ...
Yahoo Finance11d
Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting
ALTERITY THERAPEUTICS LIMITED MELBOURNE, Australia and SAN FRANCISCO, April 03, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a ...
Investing7d
Alterity Therapeutics completes placement
Alterity Therapeutics Limited (NASDAQ:ATHE), a pharmaceutical company specializing in the development of therapeutic drugs with a current market capitalization of $28 million, announced today the ...
Seeking Alpha11d
Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting
Alterity’s lead candidate, ATH434, is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has been shown preclinically to reduce α ...
Mena FN11d
Alterity Therapeutics To Deliver An Oral Presentation Of The Positive ATH434 Phase 2 Trial Results At The American Academy Of Neurology Annual Meeting
(MENAFN- GlobeNewsWire - Nasdaq) MELBOURNE, Australia and SAN FRANCISCO, April 03, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE ...